- Conditions
- Advanced Solid Tumors
- Interventions
- QTX3544, Cetuximab
- Drug · Combination Product
- Lead sponsor
- Quanta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Denver, Colorado • New Haven, Connecticut • Sarasota, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 7,390
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Cyclical Hypofractionated Palliative Radiation (Quad Shot), EORTC QLQ-C30 questionnaire
- Radiation · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Healthy
- Interventions
- PRA052, Placebo
- Drug · Other
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Solid Tumor
- Interventions
- SA53-OS (phase 1), SA53-OS (phase 2)
- Drug
- Lead sponsor
- Lamassu Bio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Cleveland, Ohio
- Conditions
- Crohns Disease
- Interventions
- TRX103, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- ZN-e4
- Drug
- Lead sponsor
- Zeno Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Duarte, California • Detroit, Michigan • East Setauket, New York + 2 more
- Conditions
- Pharmacokinetics
- Interventions
- Natrunix, Placebo
- Biological
- Lead sponsor
- XBiotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
- Interventions
- Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Celiac Disease
- Interventions
- GROW+ Project
- Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
- Interventions
- Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Irinotecan
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more
- Conditions
- Vestibular Schwannoma
- Interventions
- AAVAnc80-antiVEGF via Akouos Delivery Device
- Combination Product
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Bevacizumab, Erlotinib, Temozolomide, Radiation
- Drug · Radiation
- Lead sponsor
- Karen D. Wright MD
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Head and Neck Cancer
- Interventions
- Ad/PNP and fludarabine monophosphate
- Genetic
- Lead sponsor
- PNP Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Nashville, Tennessee
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
- Interventions
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 12 more
- Conditions
- Ulcerative Colitis
- Interventions
- High Protein and Low Fiber Diet, Low Protein and High Fiber Diet
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- nivolumab + ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dublin, Ohio
- Conditions
- Myeloma
- Interventions
- Lenalidomide, Monocyte derived DCs loaded with KRN7000
- Drug · Biological
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
- Interventions
- PDS0101, M7824, NHS-IL12
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer
- Interventions
- Autologous dendritic cell-adenovirus p53 vaccine, Carboplatin, Etoposide
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Prostate Cancer
- Interventions
- hydroxychloroquine
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 5
- States / cities
- Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
- Conditions
- Bacterial Infections
- Interventions
- XNW4107, Imipenem/Cilastatin
- Drug
- Lead sponsor
- Evopoint Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Gastrointestinal Cancer
- Interventions
- Cobimetinib, Hydroxychloroquine, Atezolizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Providence, Rhode Island
- Conditions
- Pancreatic Neoplasms
- Interventions
- DTA-H19
- Biological
- Lead sponsor
- Anchiano Therapeutics Israel Ltd.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Glioblastoma Multiforme
- Interventions
- MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Other + 2 more
- Lead sponsor
- Stanton Gerson MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio